Viewing nowCombinationLinajentaduo Tablets 2.5/850 mg
Linagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Hanil Hutech Pharmaceutical Co., Ltd.

MFDS item code 201902373 · Approved 2019.04.17 · Insurance code 649105930
Improvement of glycemic control in patients with type 2 diabetes
This medication helps improve blood sugar control by assisting in dietary regulation and exercise therapy in patients with type 2 diabetes who are using Linagliptin and Metformin together.
The dose of this medicine should be determined according to each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently treated with metformin: For patients who have not previously received pharmacological treatment for diabetes and whose blood glucose is inadequately controlled with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients whose blood glucose is inadequately controlled with metformin monotherapy: The initial dose of this medicine should provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current dose of metformin (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. 4. Patients whose blood glucose is inadequately controlled with combination therapy of metformin and a sulfonylurea: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). 5. Patients whose blood glucose is inadequately controlled with combination therapy of insulin and metformin: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with another oral antihyperglycemic agent. Any change in the treatment regimen for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who have no other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine must be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients in Whom This Medicine Must Not Be Used).
This medication may cause a rare but serious side effect called lactic acidosis, so it should not be used in patients with impaired kidney function or serious infections, dehydration, or acute cardiac problems. Patients who are allergic to any components of this medication or those with type 1 diabetes, diabetic ketoacidosis, or diabetic pre-coma should not take this medication. Women who are pregnant or nursing should avoid using this medication, and those planning to become pregnant should consider other treatment options instead of this medication. This medication can affect kidney function, so regular kidney function tests should be performed, and special caution is needed for elderly patients or those with reduced kidney function. Due to the risk of hypoglycemia, blood sugar levels should be closely monitored and dose adjustments may be necessary when taken with insulin or sulfonylureas. Severe skin and pancreatic disorders such as acute pancreatitis and bullous pemphigoid may occur; consult a doctor immediately if abdominal pain or skin abnormalities appear. This medication may lower vitamin B12 levels, so it is important to regularly check for vitamin B12 deficiency during long-term use. Before and after radiological examinations using iodinated contrast agents, this medication should be temporarily discontinued, and kidney function should be re-evaluated before resuming use. Patients undergoing surgery should stop using this medication 48 hours prior to surgery and resume only after confirming that kidney function has returned to normal post-surgery. This medication can interact with other drugs, so inform your doctor or pharmacist of any other medications being taken, especially those that may affect kidney function. The safety and efficacy in children under 10 years and adolescents aged 10 to 17 years have not been established, so the use of this medication is not recommended in these age groups. Elderly patients are at higher risk for reduced kidney function, so they should start with a low dose and monitor kidney function frequently during use. There are no studies on the effects of this medication on driving or operating machinery, so it is advisable to assess personal condition after taking it and exercise caution.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture, so it should be stored in a sealed container. The appropriate storage temperature is room temperature between 1°C and 30°C, and it should be kept away from moist areas.
Bright orange, double convex, oval film-coated tablet
30 tablets/bottle, 60 tablets/bottle, 100 tablets/bottle, 200 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationLinagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Hanil Hutech Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Anguk Pharm Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Prescription medication · Combination
Hanmi Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kukje Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
International Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.